Rapid development of drug-induced lupus nephritis in the absence of extrarenal disease in a patient receiving procainamide.
McLaughlin
K
K
Department of Nephrology, London Health Sciences Centre, Ontario, Canada. kevin.mclaughlin@lhsc.on.ca
Gholoum
B
B
Guiraudon
C
C
Jevnikar
A
A
Muirhead
N
N
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D001706:Biopsy; D003937:Diagnosis, Differential; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000150:complications; D008181:Lupus Nephritis / Q000139:chemically induced*; D008297:Male; D011342:Procainamide / Q000009:adverse effects*
D000889:Anti-Arrhythmia Agents; D011342:Procainamide